Chrono Therapeutics is a technology company.
Chrono Therapeutics has raised $80.0M across 2 funding rounds.
Chrono Therapeutics has raised $80.0M in total across 2 funding rounds.
Chrono Therapeutics is a pharmaceutical and medtech company developing wearable devices for patient-optimized drug delivery to manage addiction and chronic diseases.[1][2][3] It builds smart transdermal patches that deliver timed, algorithm-controlled doses of medications like nicotine, combined with wireless connectivity, mobile app-based behavioral support, and real-time monitoring to preempt symptom peaks.[1][4] The company serves patients with addictions (e.g., smoking cessation) and neurological disorders, addressing poor medication adherence and inconsistent dosing in traditional treatments.[4][5] Early growth included a $32 million Series A in 2016 led by Canaan Partners and 5AM Ventures, signaling strong investor confidence in its tech convergence.[4]
Founded in 2004 by Guy DiPierro, Chrono Therapeutics originated from DiPierro's vision of wearable drug delivery, initially conceptualized as a wristwatch-like device for precise medication timing.[1][3][4] DiPierro, with expertise in intellectual property and government affairs, partnered with Alan Levy—former CEO of Incline Therapeutics, which developed a fentanyl patch acquired by The Medicines Company—in 2014 to evolve the product into an arm/leg/torso-applied wearable.[4] Pivotal moments included collaborations with the University of Basel and affiliates for a drug pipeline, addition of a mobile app for behavioral support around 18 months before 2016, and the Series A funding that fueled development toward FDA clearance.[1][4]
Chrono rides the digital therapeutics and wearable medtech wave, merging pharma with IoT and AI amid rising demand for adherence solutions in chronic care—exacerbated by aging populations and post-pandemic telehealth adoption.[1][4] Timing aligns with FDA's growing support for digital health (e.g., breakthrough designations) and insurer interest in compliance-boosting tech, as seen in competitors like MediSafe or Pill Connect.[1] Market forces favor it: smoking cessation alone is a multi-billion market with poor compliance rates, while its model influences ecosystems by enabling pharma partnerships and data-driven trials.[4]
Chrono's path hinges on FDA clearance for its smoking cessation device, potentially unlocking insurer reimbursement and expansion to hypertension, pain, or neurology via its "smart" patch platform.[4] Trends like AI-personalized medicine and value-based care will propel it, evolving its influence from niche addiction tools to ecosystem shaper in programmable therapeutics—transforming passive drug delivery into proactive disease management, as envisioned from its 2004 founding.[1][2]
Chrono Therapeutics has raised $80.0M in total across 2 funding rounds.
Chrono Therapeutics's investors include 5AM Ventures, Canaan Partners, Kaiser Permanente Ventures, SR One Capital Management.
Chrono Therapeutics has raised $80.0M across 2 funding rounds. Most recently, it raised $48.0M Series B in September 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2016 | $48.0M Series B | 5AM Ventures, Canaan Partners, Kaiser Permanente Ventures, SR One Capital Management | |
| Jun 1, 2014 | $32.0M Series A | 5AM Ventures, Canaan Partners, Kaiser Permanente Ventures, SR One Capital Management |